The levels of TGF-β1 associated with EVs are related to the response of patients with HER2+ BC to HER2- targeted strategy, suggesting TGF-β1 could potentially be used as a biomarker to assess the management effectiveness. This evidence concerns the gene ERBB2 and breast cancer.